FAK Inhibitor in Patients With Advanced Solid Tumors

Inclusion Criteria: * Able to understand and voluntarily sign the written Informed Consent Form (ICF), which must be signed prior to conducting the study-specific procedures required by the trial. * At the time of signing the ICF, subjects are aged 18 to 75 years, inclusive, male and female. * Subjects must have a histologically or cytologically confirmed diagnosis of advanced or metastatic malignant solid tumor.Monotherapy dose-escalation and dose expansion: Patients with solid tumors who failed prior standard systemic therapy, have no standard treatment options, or are intolerant to standard regimens. * Prior systemic antitumor therapy must be completed at least 3 weeks before the first study drug treatment; prior small molecule TKIs or oral fluoropyrimidines require a minimum 2-week washout period. * Subjects must have at least one measurable tumor lesion per RECIST v1.1. Previously irradiated lesions should not be selected as target lesions, unless such irradiated lesion is the only measurable lesion and has documented radiological disease progression, and may then be selected as a target lesion. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Subjects have an estimated expected survival time of at least 3 months. * Has adequate organ function. * Urine protein negative or trace (±); or urine protein 1+, but urine protein to creatinine ratio (UPCR) of random morning urine \< 0.5, or 24-hour urine protein quantitation \< 0.5 g/24 h. * Fema…